Middelburg, Jim http://orcid.org/0000-0002-4797-9653
Sluijter, Marjolein
Schaap, Gaby
Göynük, Büşra
Lloyd, Katy http://orcid.org/0009-0005-4436-1232
Ovcinnikovs, Vitalijs
Zom, Gijs G.
Marijnissen, Renoud J. http://orcid.org/0000-0002-6836-675X
Groeneveldt, Christianne http://orcid.org/0000-0003-1742-1517
Griffioen, Lisa
Sandker, Gerwin G. W.
Heskamp, Sandra http://orcid.org/0000-0001-7250-0846
van der Burg, Sjoerd H.
Arakelian, Tsolere http://orcid.org/0000-0002-0079-9268
Ossendorp, Ferry http://orcid.org/0000-0001-9730-7954
Arens, Ramon http://orcid.org/0000-0001-5058-4110
Schuurman, Janine http://orcid.org/0000-0002-9738-9926
Kemper, Kristel
van Hall, Thorbald http://orcid.org/0000-0002-9115-558X
Funding for this research was provided by:
Funder: Genmab; commercial research grant; grant number: N/A Funder: Stichting Overleven met Alvleesklierkanker; project number: SOAK 17.04
Article History
Received: 13 October 2023
Accepted: 7 December 2023
First Online: 2 January 2024
Competing interests
: K.L., V.O., G.Z., R.J.M., J.S., and K.K. are employees of Genmab and have ownership interests (including stock, patents, warrants etc.). J.M., K.L., V.O., G.Z., R.J.M., J.S., K.K., and T.v.H. are inventors on a patent (WO 2022/049220 A2 entitled Antibody Therapy) involving the combination of CD3 bsAb therapy in combination with vaccination. The other authors declare that they have no competing interests.